Comparing the current results to its competitors, Astria Therapeutics Inc reported Revenue increase in the 3 quarter 2025 by 0 % year on year. The revenue growth was below Astria Therapeutics Inc 's competitors' average revenue growth of 9.57 %, achieved in the same quarter.
Astria Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 63.06 %
Astria Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with major pharmaceutical, specialty pharmaceutical, and biotechnology firms possessing greater resources and expertise. It is developing navenibart for the preventative treatment of hereditary angioedema (HAE), aiming to compete on efficacy, safety, dosing frequency, administration method, convenience, price, and reimbursement availability. The FDA has approved four on-demand HAE therapies: BERINERT, FIRAZYR, KALBITOR, and RUCONEST, as well as four long-term preventative therapies: CINRYZE, HAEGARDA, TAKHZYRO, and ORLADEYO. CSL Behring is among the primary manufacturers of HAE therapies. For moderate-to-severe atopic dermatitis (AD), the company is developing STAR-0310, which will compete with FDA-approved oral JAK inhibitors RINVOQ and CIBINQO, the EU-approved OLUMIANT, and four FDA-approved biologics: DUPIXENT, ADBRY, EBGLYSS, and NEMLUVIO. Standard care for AD also includes systemic steroids and topical treatments.
March 25, 2024
:This article provides an in-depth analysis of the positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. The study, conducted by Astria Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has demonstrated a favorable safety and tolerability profile, along with a significant reduction in mean monthly attacks of HAE. 1. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of localized swelling, leading to significant morbidity and potentially l...
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Sources:
Astria Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Astria Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
